Repetitive Transcranial Magnetic Stimulation as a Probe of Epi[INVESTIGATOR_265573]  
 
v.03.15.22 (D)   
 
 
 
 
Repetitive Transcranial Magnetic Stimulation as a 
Probe of Epi[INVESTIGATOR_265574]:  
Michael Francis, MD  
Department of Psychiatry  
IU School of Medicine 
  
[STUDY_ID_REMOVED] 
 
 
 
Repetitive Transcranial Magnetic Stimulation as a Probe of Epi[INVESTIGATOR_265573]  
 
v.03.15.22 (D)   
 
Table of Contents:  
Study Schema  
1.0 Background and Rationale  
2.0 Specific Aims and Hypothesis 
3.0 Study Design 
4.0 Study Population (Inclusion/Exclusion Criteria)  
5.[ADDRESS_322982]  
13.0 Statistical Considerations  
14.0 Data Management  
15.0 Privacy/Confidentiality Issues  
16.[ADDRESS_322983] Retention 
17.0 References  
 
 
   
 
    
 
  
  
Repetitive Transcranial Magnetic Stimulation as a Probe of Epi[INVESTIGATOR_265573]  
 
v.03.15.22 (D)  1.0 Background and Rationale  
 
Schizophrenia is a chronic and disabling illness that is associated with impairments in 
independent living as well as social and vocational functioning1. Schizophrenia also represents 
an important societal burden;  only 10% of indi viduals maintain employment, translating into 
annual lost wages of nearly $15 billion2,3. Cognitive dysfunction is a core facet of schizophrenia, 
contribut ing to profound social and vocational difficulties4-6. Epi[INVESTIGATOR_10682] (EM) is an 
important cognitive domain that is  commonly impaired in schizophrenia7.  
 
EM combines event -specific autobiographic al experiences and information regarding the 
context in which events took place8, aiding in making decisions and guiding actions in the 
present. EM deficits are associated with poor insight, poor treatment compliance, and significant 
social and occupational dysfunction8-13. There are no effective treatments for EM impairment, 
due in large part to a gap in knowledge regarding the neural mechanisms of EM dysfunction.  In 
light of the significant functional disability and poor outcomes associated with deficits in EM 
there is a critical need for more effective therapeutic options for this important cognitive deficit.  
 
Recently  research has identified that dysconnectivity in key EM structures, such as the 
precuneus, may be  associated with EM impairment,  though  the precise  role of disordered 
cortical circuitry remains elusive7,14-17. The precuneus is believed necessary for autobiographical 
and epi[INVESTIGATOR_265575]18-22. Cabeza et al. (2008) suggested that the 
precuneus is involved in supporting retrieval search, monitoring, and verification14. Altered 
function in the precuneus could be related to deficient EM functioning in various ways, including 
an impaired ability to make accurate assessments of  familiarity7. Disrupted precuneus function 
may also impair attentional networks, interfering with the ability to retrieve previously encoded 
information23. The precuneus has reciprocal connections with other brain regions, including EM 
relevant structures such as the dorsolateral prefrontal cortex (DLPFC) , the anterior cingulate 
cortex (ACC)19, and the hippocampus24. Previous studies, including our own, have 
demonstrated that altered precuneus activity is associated with EM deficits in schizophrenia
7,14,16,17,25. However, r elative to other structures,  the specific role of the precuneus 
in cognitive dysfunction in schizophrenia has not yet been determined. Clearly defining the role 
of structures, such as the precuneus, in EM dysfunction will enable investigators to develop more targeted therapeutic interventions for this important clinical phenomenon.  
 Repetitive  transcranial magnetic stimulation (rTMS) is a non- invasive neuromodulation 
technique that received FDA clearance for use in treatment resistant major depressive disorder 
in [ADDRESS_322984] provided 
evidence that low -frequency  (LF) rTMS produces an inhibitory effect on local cortical 
excitability14,17-19,21. In contrast, evidence suggests that high- frequency  (HF) rTMS produces an 
increase in local cortical excitability27-31. Studies have also demonstrated that rTMS may 
increase or decrease functional connectivity  between separate but related c ortical structures, 
utilizing high and low frequency stimulation, respectively32-35. 
  Work  by [CONTACT_265591] a viable option for investigating 
cognitive dysfunction in schizophrenia
33,35-37. We recently completed a pi[INVESTIGATOR_2268] -study investigating 
the effects of HF  rTMS, compared to sham stimulation, on cognitive dysfunction in an  early 
Repetitive Transcranial Magnetic Stimulation as a Probe of Epi[INVESTIGATOR_265573]  
 
v.03.15.22 (D)  phas e psychosis ( EPP) population. This study administered bilateral, sequential, double- blinded 
sham stimulation or HF (20 Hz ) rTMS targeting the DLPFCs in twenty subjects with EPP. Ten 
sessions of rTMS or sham were administered over the course of two- weeks. Our pi[INVESTIGATOR_2268] -study 
demonstrated not only a beneficial effect of  rTMS  on cognition but also that the intervention is  
safe and well tolerated in subjects with EPP. There were no significant adverse events during 
the course of this study and there were no significant differences in adverse events between the 
rTMS and sham group.  
   
In spi[INVESTIGATOR_265576] a treatment modality in schizophrenia, there are no 
studies  that have examined the effects of precuneus directed rTMS on either EM  deficits  or the 
neurocircuitry subserving EM  in schizophrenia. It is also important to note that the vast majority 
of studies using rTMS in schizophrenia have examined chronic populations where confounds 
associated with prolonged duration of illness may be present. EPP is a desirable population to 
study because these individuals  tend to have fewer psychiatric and physical comorbidities and 
less antipsychotic drug exposure, all of which are factors that may confound investigations of new treatment interventions for this illness. In light of the significant unmet medical need 
associated with  schizophrenia and the grave clinical effect of disrupted EM in the illness, rTMS 
modulating the precuneus , and potentially EM circuitry , represents an unexplored and 
potentially novel potential treatment option.  
 
This study proposes to combine functional magnetic resonance imaging (fMRI) with inhibitory  
LF (1 Hz) and excitatory  HF (20 Hz) rTMS  protocols to interrogate the effects of rTMS targeting 
the precuneus on: 1) precuneus activation during EM task performance; 2) functional connectivity between the precuneus and key EM circuitry, specifically the DLPFC , ACC, and 
hippocampus  and 3) performance during an in- scanner scene encoding and recognition EM 
task. This study will provide vital preliminary data on target engagement informing  future clinical 
trials seeking to utilize rTMS to treat EM impairment in schizophrenia.  This is an important 
population for study because if effective, rTMS may represent a novel  treatment for EM deficits 
in schizophrenia. This study will also seek to refine the understanding of the brain circuitry that 
mediates the potential pro- EM effects of rTMS through the use of fMRI at baseline and following 
the course of rTMS administration.  
 
2.[ADDRESS_322985] p rimary aim is to demonstrate how targeting the precuneus with rTMS impacts 
functional  activation (FA) in individuals with schizophrenia during EM  tasks. We predict  that, 
compared to sham stimulation, 1 Hz rTMS will result in decreased FA of the precuneus and 20 
Hz rTMS will result in increased FA of the precuneus.  The second primary aim  is to 
demonstrate how targeting the precuneus with rTMS impacts precuneus functional connectivity  
(FC) in individuals with schizophrenia.  We predict  that compared to sham stimulation, FC 
between the precuneus, the DLPFC,  the hippocampus,  and the ACC will be decreased  in 
response to [ADDRESS_322986] that compared to sham stimulation, 1 
Hz rTMS will impair  EM performance and that 20 Hz rTMS will improve EM performance.  
 
Repetitive Transcranial Magnetic Stimulation as a Probe of Epi[INVESTIGATOR_265573]  
 
v.03.15.22 (D)  3.[ADDRESS_322987] ten years, will be enrolled. 
Prior to randomization (Session 1), 
subjects will undergo fMRI during EM and 
RS paradigms. This baseline scan will 
also include a high- resolution structural 
sequence for neuronavigation purposes. Then on three separate days each occurring one -week 
apart, subjects will receive one session of inhibitory (1 Hz) rTMS, one session of excitatory (20 Hz) rTMS, and one sham stimulation session targeting the precuneus. The order of the three 
interventions will be randomized.  Immediately following each rTMS or sham session, subjects 
will undergo repeat fMRI during EM and RS paradigms. We will also examine the effect of rTMS 
on EM performance. 
 
rTMS  Set up and Administration 
rTMS will be delivered using the Magventure MagPro X100 Magnetic Stimulator (Magventure Inc., Alpharetta, Georgia). Motor threshold (MT) will be determined using single pulse 
stimulation over the left primary motor cortex, assessed as the lowest intensity producing five visible movements of the right abductor pollicis brevis out of ten stimulations. The Magventure 
MagPro X100 is equipped with a research- dedicated coil with combined active and sham 
stimulation capabilities. The active and sham functions share the same acoustic properties and sham mimics cutaneous stimulation, facilitating double- blinding. Study conditions (20 Hz, 1 Hz, 
sham) will be assigned a label, such as A, B, or C, by a non -blinded staff member who is not 
directly involved with the research team. Subjects will be assigned a sequence of blinded study conditions in randomized and counterbalanced fashion.  
 
High Frequency rTMS:  H
 igh frequency rTMS,  or rTMS greater than [ADDRESS_322988] utilized high frequency rTMS in 
schizophrenia populations, demonstrating that the treatment is safe, well -tolerated and capable 
of altering cognitive performance37,39. Our group has employed 20 Hz rTMS  at 110% of motor 
threshold in a stimulation protocol in- line with the current proposal to improve cognitive function 
in an EPP cohort37. High Frequency rTMS Protocol : Subjects will receive one session of high 
frequency rTMS within the following stimulation parameters: 20 Hz, at 120 % of MT, 60 trains 
(1.0 second per train), 20 pulses per train, inter -train interval of 15 seconds, for a total of 1200 
pulses over 16 minutes.  
 Low Frequency rTMS:  L
 ow frequency rTMS, or rTMS at  [ADDRESS_322989] demonstrated that a single session of 1 Hz rTMS 
is capable of inhibiting local brain activity and modulating distal but related circuitry32. This work 
is in-line with the use of 1 Hz stimulation proposed in this study.  Low Frequency rTMS Protocol:  
Subjects will receive one session of low frequency rTMS within the following stimulation parameters: Continuous 20- minute train of 1 Hz rTMS, at 120% of MT, for a total of 1200 
pulses. This protocol was shown by [CONTACT_33336]. (2013) to produce an inhibitory effect on local 
cortical excitability as well as effects on connectivity of related circuitry
32. 
Fig 1. Study Outline  
Repetitive Transcranial Magnetic Stimulation as a Probe of Epi[INVESTIGATOR_265573]  
 
v.03.15.22 (D)   
Both high and low frequency stimulation protocol s are within safety limits for rTMS28,40,41.  
 Neuronavigation 
 
Brainsight  software (Rogue Research, Montreal Canada) will 
be used to reliably target the precuneus  for stimulation. First, 
the subjectâ€™s  individual anatomy will be registered 
stereotactically  using the acquired structural MPRAGE brain 
image and fiduciary points on the scalp visible with a Polaris 
vicar camera (Brainsight software).  We will use the center of 
mass of the precuneus  (derived via Freesurfer parcellation; 
Destrieux Atlas42; left/right combined) to identify the specific 
coordinates for stimulation.  Stimulation site will be marked on a swim cap worn by [CONTACT_265592], consistent with prior TMS studies32.  
Electrical field modeling:  The processed structural image will be used to generate E -fields 
based on realistic conductor head models using SimNIBS (2.[ADDRESS_322990] version). SimNIBS 
includes volume conductor modeling (following FreeSurfer segmentation), TMS coil specific 
magnetic dipole estimations, and finite element modeling of the electric field at each tetrahedral 
element of the subjectâ€™s head mesh. In anticipation of actual TMS sessions with each patient, 
we will find the optimal TMS positioning to most strongly influence the precuneus, which will be 
the target for neuronavigated rTMS delivery. 
 rTMS  administration monitoring 
All subjects will be instructed to wear earplugs during each rTMS  session and will be monitored 
by [CONTACT_265593].   
 Duration of Treatment  
Subjects will complete three stimulation sessions ( HF, LF,  and sham) over three weeks , with 
one session occurring each week. Previous work has demonstrated that a single session of 
rTMS is sufficient to modulate target site functional activation as well as functional connectivity 
between the stimulation target and associated circuitry
32. 
 
Sample Size 
We plan to enroll 30 subjects and anticipate a 20% drop out rate, yielding [ADDRESS_322991] size 0.6; using an 
alpha level of 0.[ADDRESS_322992] significant results . 
 Clinical Research Site  
The IU Psychotic Disorders Program (IUPDP),  which is directed by  [INVESTIGATOR_124]. Alan Breier and is part of 
the IU Department of Psychiatry, is located in Indianapolis, Indiana.   IUPDP research personnel 
will manage the day -to-day activities of conducting the trial, including subject recruitment, 
consenting and screening subjects, conducting study vi sits, and performing assessments.   The 
IUPDP has [ADDRESS_322993] recruiter, one dedicated research technician, and two raters (1 Ph D, 1 Masters level) who have been trained and have extensive experience in conducting 
the assessments and cognitive tests used as outcome measures. Fig. 2 E -field precuneus modeling  

Repetitive Transcranial Magnetic Stimulation as a Probe of Epi[INVESTIGATOR_265573]  
 
v.03.15.22 (D)  4.0 Study Population (Inclusion/Exclusion Criteria)  
 
Inclusion criteria:   
1. Between 18 and 40 years of age  
2. Within 10.5 years ( 10 years , 6 months) of illness onset as defined by [CONTACT_265594]  
3. Able to give informed consent  
4. Willing and able to adhere to the study schedule 
5. Structured Clinical Interview for DSM -5 (SCID- 5)44 diagnosis of schizophrenia 
6. Clinical stability defined by:  
a. Subjects must not have experienced an exacerbation of their illness within 4 
weeks prior to randomization, leading to an intensification of psychiatric care in the opi[INVESTIGATOR_871]. Examples of intensification of care include, 
but are not limited to: inpatient hospi[INVESTIGATOR_059], day/partial hospi[INVESTIGATOR_059], 
outpatient crisis management, or psychiatric treatment in an emergency room  
AND  
b. Antipsychotic treatment stability  for at least 4 weeks prior to randomization 
(no change in antipsychotic dosing or addition of new antipsychotic 
medication)  
 
Exclusion criteria:  
1. Lifetime history of a seizure, excluding febrile seizures and those induced by 
[CONTACT_263160]  
2. First degree relative with idiopathic epi[INVESTIGATOR_105520]  
3. History of significant neurological illness  
4. History of head trauma as defined by a loss of consciousness or a post -concussive 
syndrome  
5. Pregnant  or breast feeding  
6. Known IQ < [ADDRESS_322994] participated in a clinical trial with any pharmacological treatment 
intervention for which they received study -related medication in the 4 weeks prior to 
randomization  
13. Subjects considered a high risk for suicidal acts â€“ active suicidal ideation as 
determined by [CONTACT_263161] 90 days prior to screening  
14. Current DSM -5 diagnosis of alcohol or drug use disorder  (excluding nicotine or 
caffeine)  
15. Subjects who require concomitant treatment with prohibited medication, as specified in Attachment 2  
 
 
 
 
 
Repetitive Transcranial Magnetic Stimulation as a Probe of Epi[INVESTIGATOR_265573]  
 
v.03.15.22 (D)  5.[ADDRESS_322995]- of-mouth.  
 
6.0 Clinical Assessments and Procedures  
The following assessments will be administered according to the Study Procedures Table 
(Attachment 1). All assessments will be completed by [CONTACT_265595].  
 
Columbia Suicide Severity Rating Scale (C -SSRS)  
The C -SSRS captures the occurrence, severity, and frequency of suicide- related thoughts and 
behaviors during the assessment period. The definition of behavioral suicidal events used in this 
scale is based on those used in the Columbia Suicide History Form45. During the baseline 
assessment, questions are in relation to lifetime experiences and all subsequent questioning is 
in relation to the last assessment.  
  
The Positive and Negative Syndrome Scale (PANSS)  
The PANSS is the primary assessment instrument for psychopathology. The PANSS contains 
30 items that assess symptoms of psychotic disorders including positive, negative and general 
psychopathology. The PANSS was chosen because of its widespread use in clinical studies of 
psychosis, and its demonstrated reliability in assessing psychopathology across diverse patient 
populations
46. 
 Diagnostic Interview  
The Structured Clinical Interview for DSM -5 (SCID -5-RV) will be used to confirm the diagnosis 
of a psychotic disorder and/or rule out other diagnoses. The SCID-5- RV is a semi -structured 
interview designed to evaluate DSM -5 Axis I diagnoses
44.  
 
Clinical Global Impressions Severity Scale (CGI -S)  
The CGI -S is used for repeated evaluations of global psychopathology47. The CGI -S scale is 
widely used in schizophrenia research and is a single 7- point Likert scale rating severity of 
psychopathology on a scale of 1 (normal, not ill) to 7 (very severely ill).  
 Clinical Global Impressions Severity Improvement Scale (C GI-I)  
The CGI -I is used to assess the clinical change as compared to symptoms at baseline using a 
7-point Likert scale, ranging from very much improved (1) to very much worse (7)
47. 
 
Abnormal Involuntary Movement Scale (AIMS)  
The AIMS is a 12- item scale designed to record the occurrence of dyskinetic movements48. 
Items 1 to 10 are rated on a 5- point scale, with 0 being no dyskinetic movements and 4 being 
severe dyskinetic movements. Items 11 and 12 are yes/no questions regarding the dental 
condition of a subject.  
Magnetic Resonance Imaging (MRI) Procedures  
MRI will be performed at the IU Center for Neuroimaging using an integrated 45- minute exam, 
including structural and fMRI. Scans will be completed on a research -dedicated Siemens 
MAGNETOM Prisma 3T scanner. First, we will conduct a high- resolution 3D magnetization 
Repetitive Transcranial Magnetic Stimulation as a Probe of Epi[INVESTIGATOR_265573]  
 
v.03.15.22 (D)  prepared rapid gradient echo (MPRAGE) scan for individual anatomical reference, comprised of 
160 sagittal slices with 1.0x1.0x1.2 mm voxel dimension. Subjects  will practice tasks on a 
personal computer during Visit 1 and prior to the scan at subsequent visits. An MRI -compatible 
response box will be utilized for tasks, recording reaction time and accuracy. Functional scans 
will be a cquired using T2* -weighted gradient spin echo- planar imaging (EPI) sequence with 
TR/TE 1200/[ADDRESS_322996] successfully 
implemented all tasks in multiple studies of patients with psychosis. A task -free resting state 
fMRI scan will also be acquired to measure functional connectivity between precuneus and 
associated structures and circuits.  
 
Scene Encoding and Recognition Tasks: 
These tasks utilize stimuli and a task design 
modified from that used by [CONTACT_265596]. in EM  
studies in temporal lobe epi[INVESTIGATOR_002]49,50,55. We will 
be using methods identical those in our 
previous work7. During encoding task, subjects 
view complex  scenes one at a time and are 
instructed to remember each for later 
recognition testing (Fig. 3).  Images are shown 
in a block design with interleaved 36- s image and control blocks. Image blocks consist of nine 
consecutive images, each displayed for 3.5 s, with an inter -stimulus interval (ISI) of [ADDRESS_322997] of a retiled image, repeatedly 
displayed at the same rate. Subjects do not press buttons during the encoding phase. The 
recognition task is a separate event -related fMRI paradigm administered immediately after the 
encoding phase. During the recognition task, subjects are shown the 36 scenes from the encoding phase intermixed with 36 new scenes. These images will be displayed consecutively in a pseudorandomized manner, each for 3.5 s with an ISI of 500 ms. Subjects are instructed to 
indicate, via button press, whether each displayed image was previously seen (target) or new 
(foil). Button- press responses are recorded to  assess reaction time and accuracy. Task length 
for each trial is 5:15. Different versions of the scene encoding and recognition EM tasks will be utilized, with order of administration randomized, to mitigate the potential impact of learning effects.  
 Positioning and motion 
Subjects are instructed to remain still during scanning and deformable foam cushioning is used 
to s
tabilize the head. Real time image reconstruction and processing are used for quality 
assu rance at the time of scanning. For fMRI, minor subvoxel -level translation or rotation is 
adjusted during post -processing. Noise : Noise -attenuating headphones and ear stopples 
provide excellent noise reduction and permit adequate auditory perception.  
 Func t 
ional Imaging Stimulation and Physiological Monitoring Procedures  
 A comprehensive physiological monitoring system will be used with synchronized digital 
recording including pulse oximeter, respi[INVESTIGATOR_263143], HR and BP measures, which will be available for analysis in relation to BOLD fMRI time series. 
 
  
 
 
Figure 3. Scene Encoding and  Recognition EM Task  
 
Repetitive Transcranial Magnetic Stimulation as a Probe of Epi[INVESTIGATOR_265573]  
 
v.03.15.22 (D)  7.0 Safety Assessm ents 
 
Vital Signs  
A seated blood pressure and pulse will be assessed at study visits per Study Procedures Table 
(Attachment 1).   
 
Medical History  
The subjectâ€™s lifetime medical history will be taken during the screening period. Medical history includes previous and current diseases.  
 
Physical Examination  
A physical examination including a neurological examination will be conducted as outlined in the 
Study Procedures Table.  
 
8.[ADDRESS_322998] will be conducted in all female subjects , and a urine drug screen will be 
conducted in all subjects,  as outlined in the Study Procedures Table.   
 
9.0 Concomitant Medication 
 
See Attachment 2.  
 
10.0 Adverse Events  
 
Adverse events (AEs), especially those for which the relationship to study treatment is not 
â€œunrelated,â€ will be followed up until they have returned to baseline status or stabilized at the 
discretion of the PI. If after the follow -up period, return to baseline or stabilization cannot be 
established an explanation will be recorded in the source documentation.  
 
11.0 Criteria for Repeat Assessments, Rescreening, and Discontinuation  
Repeat Assessments  
Screening assessments can be repeated within the screening window under the same 
screening number with the exception of eligibility criteria related rating scales/questionnaires. 
Subject diagnosis confirmation will not be repeated.  
 
Rescreening 
Subjects who screen fail may be rescreened one time, under the same screening number. If a 
subject is rescreened, all screening assessments (with the exception of the diagnosis 
confirmation) must be repeated and the stability criteria timelines must be met .  
 
Discontinuation  
Subjects will be discontinued under the following circumstances:  
1. During the course of the study, subjects with an interruption of stimulation  administration  
2. Subjects unwilling or unable to complete study assessments or procedures  
3. Subjects who experience seizure occurrence at any point during study participation 
4. Subjects who require a change in dose of antipsychotic medication or the addition of a 
new antipsychotic medication 
Repetitive Transcranial Magnetic Stimulation as a Probe of Epi[INVESTIGATOR_265573]  
 
v.03.15.22 (D)  5. Subjects experiencing an exacerbation of illness requiring an increased level of care or 
one judged to be clinically significant by [CONTACT_978]. 
 
If subjects discontinue from the study, completion of discontinuation assessments will be at the 
discretion of the PI.  A subject may withdraw n from the study at any time at his/her own request, 
or may be withdrawn at any time at the discretion of the PI [INVESTIGATOR_263144], behavioral, or 
administrative reasons.  
 
12.[ADDRESS_322999] (DSMB) will be 
responsible for data and safety monitoring. The DSMB is responsible for reviewing study procedures, adverse events, safety mailings (if applicable), enrollment, active subjects, and 
ongoing conduct of the research. The DSMB members can ask questions and make comments 
and/or recommendations . The IRB is notified of significant findings by [CONTACT_265597]. Due to the small sample size and single site design of this protocol, there is not sufficient justification for conducting interim analyses to examine 
trends. Data on the number of subjects enrolled and the number of adverse events will be 
reviewed by [CONTACT_265598]. The resultant report will 
be issued to the Indiana Uni versity IRB at least at the time of continuing review or more 
frequently by [CONTACT_32236]. Any unanticipated events will be immediately directed to the PI [INVESTIGATOR_265577].  
 
13.[ADDRESS_323000] of precuneus directed rTMS on EM 
performance or neurocircuitry, there are no known calculations with EPP patients. We plan to 
enroll 30 subjects and anticipate a 20% drop out rate, thus yielding [ADDRESS_323001] size 0.6; using an alpha level of 0.[ADDRESS_323002] the significant results.  
 Statistical Analyses  
 Intent -to-treat (ITT) analysis will be conducted, and thus all randomized subjects will be 
included. ITT is the most conservative approach for detecting a treatment effect, because the 
inclusion of subjects who do not complete the intervention will serve to underestimate rather 
than overestimate any treatment effect. Sensitivity analyses including a subset analysis using a 
â€œcompleters onlyâ€ analysis will be performed to test the robustness of the findings. Statistical tests will be performed based on two- sided test at the 5% level of significance.  
Repetitive Transcranial Magnetic Stimulation as a Probe of Epi[INVESTIGATOR_265573]  
 
v.03.15.22 (D)  Descriptive characteristics at baseline will be summarized for the whole sa mple. For continuous 
variables, the mean and standard deviation will be presented. For categorical variables, the 
number and percent will be reported.  
 
Primary analyses: For each subject, change scores in activation of the precuneus (aim 1), 
functional connectivity (aim 2), and EM performance (aim 3) will be calculated at each treatment 
by [CONTACT_2329] (post - baseline). We will employ a mixed model for repeated measures ANCOVA, of 
the general form for each measure: ð‘ð‘â„Žð‘Žð‘Žð‘Žð‘Žð‘Žð‘Žð‘Žð‘Žð‘–ð‘–ð‘–ð‘–ð‘–ð‘–=ðœ‡ðœ‡+ð›¼ð›¼ð‘–ð‘–+ð‘ð‘ð‘–ð‘–ð‘–ð‘–+ð›¾ð›¾ð‘–ð‘–+ð›½ð›½ð‘‹ð‘‹ð‘–ð‘–ð‘–ð‘–ð‘–ð‘–+ðœðœð‘‘ð‘‘(ð‘–ð‘–,ð‘˜ð‘˜)+ð‘Žð‘Žð‘–ð‘–ð‘–ð‘–ð‘–ð‘–, 
where ðœ‡ðœ‡ is overall mean; ð›¼ð›¼ ð‘–ð‘– is the effect of the ð‘–ð‘–th treatment sequence ( ð‘–ð‘–= 1, 2,â‹¯, 6); ð‘ð‘ð‘–ð‘–ð‘–ð‘– is the 
random effect with variance ðœŽðœŽð‘ð‘2 for the ð‘—ð‘—th subject ( ð‘—ð‘—= 1, 2,â‹¯,24) of the ð‘–ð‘– th treatment sequence; 
ð›¾ð›¾ð‘–ð‘– is the period effect ( ð‘˜ð‘˜= 1, 2, 3); ð›½ð›½ð‘‹ð‘‹ is  the baseline value; ðœðœð‘‘ð‘‘(ð‘–ð‘–,ð‘˜ð‘˜) is the direct effect of the 
treatment administered in period ð‘˜ð‘˜ of sequence group ð‘–ð‘–;  and ð‘Žð‘Žð‘–ð‘–ð‘–ð‘–ð‘–ð‘– is the random error with 
variance ðœŽðœŽ2 for the subject in period ð‘˜ð‘˜. Based on this model, we will compare the treatment 
difference in change score between [ADDRESS_323003] model will provide the unbiased estimates60. 
Secondary analyses:  We expect two mediation relations: (1) the treatment affects the 
connectivity through the activation of the precuneus; and (2) the treatment affects the EM performance through the activation of the precuneus.  We use the first mediation as an 
example. The following 3 equations proposed by [CONTACT_265599]
61: ð‘ð‘â„Žð‘Žð‘Žð‘Žð‘Žð‘Žð‘Žð‘Žð‘Žð‘–ð‘–ð‘–ð‘–ð‘–ð‘–=ðœ‡ðœ‡+ð›¼ð›¼ð‘–ð‘–+ð‘ð‘ð‘–ð‘–ð‘–ð‘–+ð›¾ð›¾ð‘–ð‘–+ð›½ð›½ð‘‹ð‘‹ð‘–ð‘–ð‘–ð‘–ð‘–ð‘–+ðœðœð‘‘ð‘‘(ð‘–ð‘–,ð‘˜ð‘˜)+ð‘Žð‘Žð‘–ð‘–ð‘–ð‘–ð‘–ð‘– (1); ð‘ð‘â„Žð‘Žð‘Žð‘Žð‘Žð‘Žð‘Žð‘Žð‘Žð‘–ð‘–ð‘–ð‘–ð‘–ð‘–=
ðœ‡ðœ‡+ð›¼ð›¼ð‘–ð‘–+ð‘ð‘ð‘–ð‘–ð‘–ð‘–+ð›¾ð›¾ð‘–ð‘–+ð›½ð›½ð‘‹ð‘‹ð‘–ð‘–ð‘–ð‘–ð‘–ð‘–+ð›¾ð›¾ð‘€ð‘€ð‘–ð‘–ð‘–ð‘–ð‘–ð‘–+ðœðœð‘‘ð‘‘(ð‘–ð‘–,ð‘˜ð‘˜)+ð‘Žð‘Žð‘–ð‘–ð‘–ð‘–ð‘–ð‘– (2);and ð‘€ð‘€ð‘–ð‘–ð‘–ð‘–ð‘–ð‘–=ðœ‡ðœ‡+ð›¼ð›¼ð‘–ð‘–+ð‘ð‘ð‘–ð‘–ð‘–ð‘–+ð›¾ð›¾ð‘–ð‘–+ð›½ð›½ð‘‹ð‘‹ð‘–ð‘–ð‘–ð‘–ð‘–ð‘–+
ðœðœð‘‘ð‘‘(ð‘–ð‘–,ð‘˜ð‘˜)+ð‘Žð‘Žð‘–ð‘–ð‘–ð‘–ð‘–ð‘– (3). Four steps are to be evaluated. First, a significant relation of treatment to the 
change in connectivity is required in (1). Second, a s ignificant relation of treatment to the 
change in activation of the precuneus is required in (3). Third, mediator, the change in the 
activation of the precuneus, must be significantly associated with change in connectivity when both treatment and mediator are controlled as covariates. Fourth, the coefficients of treatment in 
(1) must be larger (in absolute value) than the coefficients of treatments in (2)
62. If four steps are 
met, we will consider that the change in activation of the precuneus is mediator of the 
relationship between treatment and change in connectivity.  
 
 
 
 
Treatment  
Mediator: change in 
activation of the 
precuneus 
Change in Connectivity  
a 
 b 
câ€™ 
Repetitive Transcranial Magnetic Stimulation as a Probe of Epi[INVESTIGATOR_265573]  
 
v.03.15.22 (D)   
 
 
Brain Imaging Analyses: Aim 1 . D ata analysis of the blood- oxygen level -dependent (BOLD) 
time series will utilize standard preprocessing through the AFNI software package. Standard 
preprocessing includes motion correction, despi[INVESTIGATOR_28884], detrending, smoothing, and exclusion of signal and motion outlier time points. Each conditionâ€™s timing will be convolved with a 
hemodynamic response function to model an ideal response for that condition. General linear 
modeling will provide a regression coefficient estimate (beta) of the BOLD response to eac h 
condition (Target correct; Foil correct; Target incorrect; Foil incorrect). We will also include regressors of no interest for motion and motion derivatives to reduce noise. For our primary analysis, we will create a region of interest (ROI) as a [ADDRESS_323004]: Each event type will be modeled separately. Brain 
activity will be examined by [CONTACT_265600] 
(Target correct vs. Foil correct). We wi ll extract the mean response from this contrast from 
our precuneus ROI  and evaluate the aim via a mixed model for repeated measures. Aim 2.  
Beyond standard preprocessing, time -series data will be filtered to extract low frequency (< 0.08 
hz) BOLD data. The ANATICOR approach (within AFNI) will be used63 to reduce noise from 
physiol ogical or hardware sources. ANATICOR utilizes tissue segmentation to control for 
spatially coherent fluctuations emanating from non- gray matter. Structural regions of interest 
(ROIs) will be defined on each side with Talairach -based atlases available via A FNI software for 
the ACC and bilateral middle frontal gyrus, in addition to the spherical precuneus ROI. Visual 
inspection of ROIs will ensure their correct position. The mean preprocessed time series will be extracted from each ROI, and time -series correl ations between ROIs will be calculated. These 
correlations will be used as the dependent variable in a mixed model for repeated measures ANCOVA, with post- hoc tests as necessary. Supplementary analyses will examine connectivity 
differences of the precuneus  ROI across the entire brain (corrected p < .05).  
 
14.[ADDRESS_323005] ored in 
separate electronic files and merged with primary data as needed. The imaging data will automatically be stripped of all PHI prior to uploading to the database. Quality assurance steps 
will include: 1)  Quality control data checks after each visit,  2) Single data entry by [CONTACT_464], and 
3) Data verification procedures throughout the study to ensure proper transfer of data from paper source to REDCap.  
 
Treatment  
Mediator: change in 
activation of the precuneus   
Change in EM performance  
Repetitive Transcranial Magnetic Stimulation as a Probe of Epi[INVESTIGATOR_265573]  
 
v.03.15.22 (D)  15.0 Privacy/Confidentiality Issues  
 
Confidentiality will be protected by [CONTACT_263164], coding all subject information when 
possible, and by [CONTACT_263165] a locked filing cabinet or on secured databases with 
access available only to the PI [INVESTIGATOR_27235]. Furthermore, data entered into a computer 
database will only use subject codes on secured computers that will be password protected with access available only to the PI [INVESTIGATOR_27235]. Any screening information obtained from 
potential research subjects who subsequently do not participate in the research study will be 
destroyed.  
 
16.[ADDRESS_323006] Retention  
 Paper copi[INVESTIGATOR_265578] y ears after 
the study is closed with the IRB. One year after study closure, the documents will be shipped to 
the Indiana University Department of Psychiatry long- term storage facility until destruction.  
 
  
Repetitive Transcranial Magnetic Stimulation as a Probe of Epi[INVESTIGATOR_265573]  
 
v.03.15.22 (D)  17.[ADDRESS_323007] of schizophrenia:  focus on vocational impairment. The Economics of 
Neuroscience. 2000;2:42- 48. 
2. Rupp A, Keith SJ. The costs of schizophrenia. Assessing the burden. The Psychiatric clinics of North America. Jun 1993;16(2):413- 423. 
3. Sevy S, Davidson M. The cost of cognitive impairment in schizophrenia. Schizophrenia research. 
Sep 1995;17(1):1- 3. 
4. Harvey PD, Bowie CR, Friedman JI. Cognition in schizophrenia. Current psychiatry reports. Oct 2001;3(5):423- 428. 
5. Palmer BW, Heaton, R .K., Paulsen, J.S., Kuck, J., Braff, D., Harris, M.J., Zisoonk, S., Jesta, D.V. 
Is it possible to be schizophrenic and yet neuropsychologically normal? Neuropsychology. 
1997;11:437- 446. 
6. Sponheim SR, Jung RE, Seidman LJ, et al. Cognitive deficits in recent -onset and chronic 
schizophrenia. Journal of psychiatric research. May 2010;44(7):421- 428. 
7. Francis MM, Hummer TA, Vohs JL, et al. Functional neuroanatomical correlates of epi[INVESTIGATOR_265579]. Brain Imaging Behav. Mar 2016;10(1):1- 11. 
8. Danion JM, Huron C, Vidailhet P, Berna F. Functional mechanisms of epi[INVESTIGATOR_265580]. Canadian journal of psychiatry. Revue canadienne de psychiatrie. 
Nov 2007;52(11):693- 701. 
9. Achim AM, Lepage M. Is associative recognition more impaired than item recognition memory in 
Schizophrenia? A meta- analysis. Brain and cognition. Nov 2003;53(2):121- 124. 
10. Aleman A, Hijman R, de Haan EH, Kahn RS. Memory impairment in schizophrenia: a meta-
analysis. The American journal of psychiatry. Sep 1999;156(9):1358- 1366.  
11. Gold JM, Randolph C, Carpenter CJ, Goldberg TE, Weinberger DR. Forms of memory failure in 
schizophrenia. Journal of abnormal psychology. Aug 19 92;101(3):487- 494. 
12. Leavitt VM, Goldberg TE. Epi[INVESTIGATOR_265581]. Neuropsychology review. Sep 
2009;19(3):312- 323. 
13. Snitz BE, Macdonald AW, 3rd, Carter CS. Cognitive deficits in unaffected first -degree relatives of 
schizophrenia patients:  a meta- analytic review of putative endophenotypes. Schizophrenia 
bulletin. Jan 2006;32(1):179- 194. 
14. Cabeza R, Ciaramelli E, Olson IR, Moscovitch M. The parietal cortex and epi[INVESTIGATOR_10682]: an attentional account. Nature reviews. Neuroscience. Aug 2008;9(8):613- 625. 
15. Heckers S. Neuroimaging studies of the hippocampus in schizophrenia. Hippocampus. 
2001 ;11(5):520- 528. 
16. Lepage M, Pelletier M, Achim A, Montoya A, Menear M, Lal S. Parietal cortex and epi[INVESTIGATOR_265582]. Psychiatry research. Jun 30 2010;182(3):191- 199. 
17. Ragland JD, Gur RC, Valdez J, et al. Event -related fMRI of frontotemporal activity during word 
encoding and recognition in schizophrenia. The American journal of psychiatry. Jun 
2004;161(6):1004- 1015.  
18. Cavanna AE. The precuneus and consciousness. CNS spectrums. Jul 2007;12(7):545- 552. 
19. Cavanna AE, Trimble MR . The precuneus: a review of its functional anatomy and behavioural 
correlates. Brain : a journal of neurology. Mar 2006;129(Pt 3):564- 583. 
20. Gusnard DA, Raichle ME, Raichle ME. Searching for a baseline: functional imaging and the 
resting human brain. Nature reviews. Neuroscience. Oct 2001;2(10):685- 694. 
21. Kuhn S, Gallinat J. Resting -state brain activity in schizophrenia and major depression: a 
quantitative meta- analysis. Schizophrenia bulletin. Mar 2013;39(2):358- 365. 
22. van der Meer L, Costafreda S, Aleman A, David AS. Self -reflection and the brain: a theoretical 
review and meta- analysis of neuroimaging studies with implications for schizophrenia. 
Neuroscience and biobehavioral reviews. May 2010;34(6):935- 946. 
23. Fransson P, Marrelec G. The precuneus /posterior cingulate cortex plays a pi[INVESTIGATOR_265583]: Evidence from a partial correlation network analysis. NeuroImage. Sep 1 
2008;42(3):1178- 1184.  
24. Achim AM, Lepage M. Epi[INVESTIGATOR_10682] -related activation in schizophrenia: meta- analysis. The 
British journal of psychiatry : the journal of mental science. Dec 2005;187:500- 509. 
Repetitive Transcranial Magnetic Stimulation as a Probe of Epi[INVESTIGATOR_265573]  
 
v.03.15.22 (D)  25. Heckers S, Curran T, Goff D, et al. Abnormalities in the thalamus and prefrontal cortex during 
epi[INVESTIGATOR_265584]. Biological psy chiatry. Oct 1 2000;48(7):651- 657. 
26. Machii K, Cohen D, Ramos -Estebanez C, Pascual -Leone A. Safety of rTMS to non- motor cortical 
areas in healthy participants and patients. Clinical neurophysiology : official journal of the International Federation of Cl inical Neurophysiology. Feb 2006;117(2):455- 471. 
27. Chen R, Seitz RJ. Changing cortical excitability with low -frequency magnetic stimulation. 
Neurology. Aug 14 2001;57(3):379- 380. 
28. Rossi S, Hallett M, Rossini PM, Pascual -Leone A. Safety, ethical considerations, and application 
guidelines for the use of transcranial magnetic stimulation in clinical practice and research. 
Clinical neurophysiology : official journal of the International  Federation of Clinical 
Neurophysiology. Dec 2009;120(12):2008- 2039.  
29. Hallett M. Transcranial magnetic stimulation: a primer. Neuron. Jul 19 2007;55(2):187- 199. 
30. Pascual -Leone A, Grafman J, Hallett M. Modulation of cortical motor output maps during 
development of implicit and explicit knowledge. Science. Mar 4 1994;263(5151):1287- 1289.  
31. Fitzgerald PB, Fountain S, Daskalakis ZJ. A comprehensive review of the effects of rTMS on 
motor cortical excitability and inhibition. Clinical neurophysiology : of ficial journal of the 
International Federation of Clinical Neurophysiology. Dec 2006;117(12):2584- 2596.  
32. Chen AC, Oathes DJ, Chang C, et al. Causal interactions between fronto- parietal central 
executive and default -mode networks in humans. Proceedings of the National Academy of 
Sciences of the [LOCATION_002] of America. Dec 3 2013;110(49):[ZIP_CODE]- [ZIP_CODE].  
33. Graziano B, Kaskie, R. E., & Ferrarelli, F. Transcranial Magnetic Stimulation (TMS) as a treatment tool in schizophrenia: A review. . Journal of Brain and Neurology,. 2017;1(1):14- 24. 
34. Driver J, Blankenburg F, Bestmann S, Vanduffel W, Ruff CC. Concurrent brain- stimulation and 
neuroimaging for studies of cognition. Trends in cognitive sciences. Jul 2009;13(7):319- 327. 
35. Brady RO, Jr., Gonsalvez I, Lee I, et al. Cerebellar -Prefrontal Net work Connectivity and Negative 
Symptoms in Schizophrenia. The American journal of psychiatry. Jan 30 2019:appi[INVESTIGATOR_207664]201818040429.  
36. Slotema CW, Blom JD, Hoek HW, Sommer IE. Should we expand the toolbox of psychiatric 
treatment methods to include Repetitive Transcranial Magnetic Stimulation (rTMS)? A meta-
analysis of the efficacy of rTMS in psychiatric disorders. The Journal of clinical psychiatry. Jul 2010;71(7):873- 884. 
37. Francis MM, Hummer, T.A., Vohs, J.L., Yung, M.G., Visco, A.C., Mehdiyoun, N.F., Kuli g, T.C., 
Um, M., Yang, Z., Motamed, M., Liffick, E., Zhang, Y., Breier, A. Cognitive effects of bilateral high 
frequency repetitive transcranial magnetic stimulation in early phase psychosis: a pi[INVESTIGATOR_799]. 
Brain Imaging and Behavior. 2018;(In Press).  
38. Siebner HR, Rothwell J. Transcranial magnetic stimulation: new insights into representational 
cortical plasticity. Experimental brain research. Jan 2003;148(1):1- 16. 
39. Barr MS, Farzan F, Rajji TK, et al. Can repetitive magnetic stimulation improve cognit ion in 
schizophrenia? Pi[INVESTIGATOR_26923] a randomized controlled trial. Biological psychiatry. Mar 15 
2013;73(6):510- 517. 
40. Wassermann EM. Risk and safety of repetitive transcranial magnetic stimulation: report and 
suggested guidelines from the Internationa l Workshop on the Safety of Repetitive Transcranial 
Magnetic Stimulation, June 5- 7, 1996. Electroencephalography and clinical neurophysiology. Jan 
1998;108(1):1- 16. 
41. Chen R, Gerloff C, Classen J, Wassermann EM, Hallett M, Cohen LG. Safety of different inter -
train intervals for repetitive transcranial magnetic stimulation and recommendations for safe 
ranges of stimulation parameters. Electroencephalography and clinical neurophysiology. Dec 
1997;105(6):415- 421. 
42. Destrieux C, Fischl B, Dale A, Halgren E. Automatic parcellation of human cortical gyri and sulci using standard anatomical nomenclature. NeuroImage. Oct 15 2010;53(1):1- 15. 
43. Breier A, Buchanan RW, D'Souza D , et al. Herpes simplex virus 1 infection and valacyclovir 
treatment in schizophrenia: Results from the VISTA study. Schizophrenia research. Nov [ADDRESS_323008] MB, Williams, J.B.W., Karg, R.S., & Spi[INVESTIGATOR_626], R.L. Structured clinical interview for DSM -5 
disorders, clinician version (SCID -5-CV). Arlington, VA: American Psychiatric Association; 2015.  
Repetitive Transcranial Magnetic Stimulation as a Probe of Epi[INVESTIGATOR_265573]  
 
v.03.15.22 (D)  45. Posner K, Brent, D., Lucas, C., Gould, M., Stanley, B., Brown, G., Fisher, P., Zelazny, J., Burke, 
A., Oquendo, M., & Mann, J. Columbia- suicide severity rati ng scale (C -SSRS). [LOCATION_001], NY: 
Columbia University Medical Center; 2008.  
46. Kay SR, Fiszbein A, Opler LA. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophrenia bulletin. 1987;13(2):261 -276. 
47. Guy W. ECDEU assessment manual for psychopharmacology, revised. Rockville, MD: National 
Institute of Mental Health.  Psychopharmacology Research Branch;1976.  
48. Branch PR. U.S. Department of Health, Education, and Welfare:  Abnormal Involuntary 
Movement Scale. 1975.  
49. Detre JA, Maccotta L, King D, et al. Functional MRI lateralization of memory in temporal lobe epi[INVESTIGATOR_002]. Neurology. Apr 1998;50(4):926- 932. 
50. Killgore WD, Glosser G, Casasanto DJ, French JA, Alsop DC, Detre JA. Functional MRI and the 
Wada test provide complementary information for predicting post -operative seizure control. 
Seizure : the journal of the British Epi[INVESTIGATOR_265585]. Dec 1999;8(8):450- 455. 
51. McAllister TW, Saykin AJ, Flashman LA, et al. Brain activation during working memory 1 month 
after mild traumatic brain injury: a functional MRI study. Neurology. Oct 12 1999;53(6):1300- 1308.  
52. McAllister TW, Sparling MB, Flashman LA, Guerin SJ, Mamourian AC, Saykin AJ. Differential working memory load effects after mild traumatic brain injury. NeuroImage. Nov 2001;1 4(5):1004-
1012.  
53. McDonald BC, Saykin AJ, Williams JM, Assaf BA. fMRI Wada test: prospects for presurgical 
mappi[INVESTIGATOR_265586]. In: Faro SH, Mohamed FB, eds. Functional MRI: Basic 
Principles and Clinical Applications . [LOCATION_001]: Springer; 2006: 278-314. 
54. McDonald BC, Saykin AJ. Functional magnetic resonance imaging in neurosurgical planning for 
temporal lobe epi[INVESTIGATOR_002]: language, memory, and seizure outcome. In: Hillary FG, DeLuca J, eds. 
Functional Neuroimaging in Clinical Populations . [LOCATION_001] : Guilford Press; 2007:185- 218. 
55. Rabin ML, Narayan VM, Kimberg DY, et al. Functional MRI predicts post -surgical memory 
following temporal lobectomy. Brain : a journal of neurology. Oct 2004;127(Pt 10):2286- 2298.  
56. Saykin AJ, Flashman LA, Frutiger S, et al. Semantic processing and memory in Alzheimer's 
disease: fMRI activation patterns. J Int Neuropsychol Soc. 1998;4:49.  
57. Saykin AJ, Flashman LA, McAllister TW, et al. Semantic, phonological and epi[INVESTIGATOR_265587]: Functional MRI activation patterns indicate a need for new models 
of dysfunction. Schizophr Res. 1999;36:233.  
58. Saykin AJ, Wishart HA, Rabin LA, et al. Cholinergic enhancement of frontal lobe activity in mild 
cognitive impairment . Brain : a journal of neurology. Jul 2004;127(Pt 7):1574- 1583.  
59. Wishart HA, Saykin AJ, McDonald BC, et al. Brain activation patterns associated with working memory in relapsing- remitting MS. Neurology. Jan 27 2004;62(2):234- 238. 
60. Fitzmaurice GM, Lai rd, N.M., & Ware, J.H. Applied longitudinal analysis.  Vol 998: John Wiley & 
Sons; October 23, 2012.  
61. Baron RM, Kenny DA. The moderator -mediator variable distinction in social psychological 
research: conceptual, strategic, and statistical considerations.  Journal of personality and social 
psychology. Dec 1986;51(6):1173- 1182.  
62. MacKinnon DP, Fairchild AJ, Fritz MS. Mediation analysis. Annual review of psychology. 
2007;58:593- 614. 
63. Jo HJ, Saad ZS, Simmons WK, Milbury LA, Cox RW. Mappi[INVESTIGATOR_265588], with artifact detection and removal. NeuroImage. Aug 15 2010;52(2):571- 582. 
  
Repetitive Transcranial Magnetic Stimulation as a Probe of Epi[INVESTIGATOR_265573]  
 
v.03.15.22 (D)   
ATTACHMENT 1: Study Procedures Table 
 
Visit Number  1c 2 3 4 5d 
Dayb  0 7 14 28 
Informed Consent  X     
Screening (Demographics, Inc/Exc, 
Medical & Psychiatric History of Self and 
Family)  X     
SCID Va X     
Physical Exam  X     
CGI-S X X X X  
CGI-I  X X X  
Vitals  X X X X  
Urine Drug Screen  X     
Pregnancy Test  X X X X  
Motor Threshold Determination  X     
MRI â€“ Baseline  & Baseline EM Task  X     
Randomization (Order of Study 
Intervention)   X    
Neuro Navigation   X X X  
rTMS /sham  Administration   X X X  
Post Stimulation MRI -EM Task    X X X  
PANSS  X     
AIMS  X X X X  
C-SSRS  X X X X  
Adverse Events  X X X X X 
Concomitant Medication  X X X X X 
aIf subject received a SCID interview within 6 months of screening, it may not be repeated at 
the discretion of the PI  
[INVESTIGATOR_265589].  A 
total of 3 sessions. Visit window deviations will be granted at the discretion of the PI [INVESTIGATOR_265590] a protocol violation. 
cVisit window for Visit 1 is 0 -30 days  
dVisit 5 may occur by [CONTACT_263166] 14 days after Visit 4. Visit window 
deviations will be granted at the discretion of the PI [INVESTIGATOR_263146] a protocol violation.  
 
Repetitive Transcranial Magnetic Stimulation as a Probe of Epi[INVESTIGATOR_265573]  
 
v.03.15.22 (D)  Attachment 2:  Concomitant Medication Table  
 
Medication  Allowed  Notes  
Amitriptyline  No  
Amphetamines et., methylphenidate, 
dextroamphetamine)  No  
Antiemetics (eg., metoclopramide, 
domperidone, others with dopamine 
blocking properties)  No  
Antiepi[INVESTIGATOR_263147], no changes or 
additions  
Antihistam ines, nonsedating (eg., 
loratidine, fexofenadine, cetirizine)  Yes  
Antihistamines, sedating (eg., 
diphenhydramine, hydroxyzine, 
meclizine, benztropi[INVESTIGATOR_050])  Yes-Epi[INVESTIGATOR_263148] 24 hours of cognitive 
assessments  
Antipsychotic medications  Yes Stable dose over four weeks prior 
to randomization, no changes or 
additions during duration of trial  
Barbiturates  No  
Benzodiazepi[INVESTIGATOR_263149]-Epi[INVESTIGATOR_263148] 24 hours of cognitive 
assessments  
Chlorpromazine  No  
Bupriopi[INVESTIGATOR_263150] (eg., 
pseudophedrine)  Yes-epi[INVESTIGATOR_263151] 24 hours of cognitive 
assessments  
Doxepi[INVESTIGATOR_263152] w/ primary CNS 
activity  No  
Lithium  Yes  
MAOIs  Yes  
Methadone  No  
Mirtazepi[INVESTIGATOR_263153], no changes or 
additions  
Muscle Relaxants  Yes-Epi[INVESTIGATOR_263148] 24 hours of cognitive 
assessments  
Nicotine Replacement  Yes  
Nortriptyline  No  
Opi[INVESTIGATOR_263154] (eg., Zolpi[INVESTIGATOR_6730])  Yes-Epi[INVESTIGATOR_263148] 24 hours of cognitive 
assessments  
SNRIs  Yes  
SSRIs  Yes  
Tricyclic antidepressants  Yes  
Trazodone  Yes-Epi[INVESTIGATOR_263155]   